1

                                                                    EXHIBIT 99.2


                               CELL GENESYS, INC.
                CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS
                      TWELVE MONTHS ENDED DECEMBER 31, 1997
                                 (IN THOUSANDS)
                                   (UNAUDITED)




                                     Cell
                                     Genesys,     Abgenix,     Elimination
                                     Inc.         Inc.         Entries      Consolidated
                                                                      
Revenue under collaborative
   agreements - principally
   from related parties (net
   of equity in losses of the
   Xenotech joint venture of
   $897, $3,866 and $1,702)          $  21,961    $   1,954    $    (109)   $  23,806

Operating expenses:
     Research and development           25,534       11,405         (109)      36,830
     General and administrative          7,278        3,381                    10,659
     Charge for purchased
       in-process technology            72,270         --                      72,270
     Restructuring charge related
       to acquisition                    6,576         --                       6,576
     Charge for cross-license and
       settlement (includes
       $11,250 equity in losses of
       Xenotech joint venture
       associated with
       cross-license and            
       settlement)                        --         22,500                    22,500  
                                     ---------    ---------                 ---------
       Total operating expenses        111,658       37,286                   148,835
                                     ---------    ---------                 ---------

Interest income                          3,842          307         (196)       3,953
Interest expense                        (1,938)        (711)         196       (2,453)
                                     =========    =========    =========    =========
Net loss                             $ (87,793)   $ (35,736)   $    --      $(123,529)
                                     =========    =========    =========    =========